RxDoctor Payments Data

Melissa Francis

Adult Health · West Haven, CTNPI 1194187070

Payments from drug & device makers

$2,032in general payments, 2019–2025

Across 89 payments — averaging $22.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$508
  • Boehringer Ingelheim$354
  • Lilly USA, LLC$249
  • AbbVie$203
  • Merck$156
  • Otsuka America Pharmaceutical, Inc.$125
  • plus $438 from 11 others

What the payments were for

  • Food & beverage$2,032100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,032 in reported general payments places this provider in the 75th percentile of 418 adult health providers in Connecticut.

See all adult health providers in Connecticut

Medicare billing

Part B allowed, 2024
$82,446
Medicare patients
118
Services billed
707

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban68$57,599
JardianceEmpagliflozin20$12,002
Trelegy ElliptaFluticasone/Umeclidin/Vilanter12$10,573
JanuviaSitagliptin Phosphate15$8,270
Breo ElliptaFluticasone/Vilanterol18$8,071
TradjentaLinagliptin16$7,678
Divalproex Sodium34$3,375
Trazodone Hcl162$1,847
Atorvastatin Calcium161$1,791
Levothyroxine Sodium119$1,135
Escitalopram Oxalate57$928
Metoprolol Succinate73$848
Rosuvastatin Calcium51$803
Mirtazapine28$778
Duloxetine Hcl25$758

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$31$57,59968 claims
Boehringer IngelheimJardiance, Tradjenta$354$19,68136 claims
GSKTrelegy Ellipta, Breo Ellipta$508$18,64430 claims
MerckJanuvia$156$8,27015 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 418 adult health providers in Connecticut.

Other adult health in West Haven

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →